GlassScriptPhysician profile
Joshua B Leblanc
NPI 1407868987
$4,790.40
in general payments reported to CMS, 2019-2025
32 companies · $643 in 2025
The $643 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $220 · 2021: $1,054 · 2022: $1,049 · 2023: $767 · 2024: $693 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,103.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,304.73 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $794.50 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Glaxosmithkline, LLC. | $485.38 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Pfizer INC. | $257.89 | 2019-2025 | |
| Genzyme Corporation | $230.21 | 2023-2024 | |
| Ironshore Pharmaceuticals INC. | $211.61 | 2019-2024 | Jornay Pm |
| Corium, LLC | $207.45 | 2022-2025 | Azstarys |
| Sanofi Pasteur INC. | $159.31 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $137.78 | 2021-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Medtronic, INC. | $114.34 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.28 | 2019-2021 | |
| Cranial Technologies, INC | $91.73 | 2024-2025 | Doc Band |
| Seqirus USA INC | $91.21 | 2022-2023 | Flucelvax Quadrivalent |
| Collegium Pharmaceutical, INC. | $88.42 | 2025 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $70.23 | 2024-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lnhc, INC | $54.93 | 2025 | Zelsuvmi |
| Neos Therapeutics, LP | $45.61 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $41.21 | 2022 | |
| Noven Therapeutics, LLC | $35.00 | 2023-2024 | Xelstrym |
| Ars Pharmaceuticals Operations, INC. | $28.19 | 2025 | Neffy |
| Shire North American Group INC | $28.03 | 2019 | |
| Genentech USA, INC. | $23.87 | 2020-2021 | |
| Verrica Pharmaceuticals INC. | $22.38 | 2023 | Ycanth |
| Azurity Pharmaceuticals, INC. | $20.80 | 2025 | Alvesco |
| Vertical Pharmaceuticals, LLC | $19.93 | 2025 | Relexxii |
| Cipher Pharmaceuticals US LLC | $19.69 | 2025 | Natroba, Spinosad |
| Phadia US INC. | $18.34 | 2023 | Immunocap |
| Hologic Sales and Service, LLC | $17.22 | 2021 | |
| Mission Pharmacal Company | $17.14 | 2019 | |
| Adlon Therapeutics L.P. | $16.41 | 2021 | |
| Sobi, INC | $14.67 | 2019 | |
| Bardy Diagnostics, INC. | $9.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Leblanc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.